Disc Medicine Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DISC MEDICINE, INC. | ||
| Date: March 21, 2024 | By: | /s/ Jean Franchi |
|---|---|---|
| Jean Franchi | ||
| Chief Financial Officer(Principal Financial and Accounting Officer) | ||
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints each of John Quisel, J.D., Ph.D., Jean Franchi and Rahul Khara, Pharm.D., J.D., acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ John Quisel | President, Chief Executive Officer and Director(Principal Executive Officer) | March 21, 2024 |
| John Quisel, J.D., Ph.D. | ||
| /s/ Jean Franchi | Chief Financial Officer(Principal Financial and Accounting Officer) | March 21, 2024 |
| Jean Franchi | ||
| /s/ Donald Nicholson | Director | March 21, 2024 |
| Donald Nicholson, Ph.D. | ||
| /s/ Kevin Bitterman | Director | March 21, 2024 |
| Kevin Bitterman, Ph.D. | ||
| /s/ Liam Ratcliffe | Director | March 21, 2024 |
| Liam Ratcliffe, M.D., Ph.D. | ||
| /s/ William White | Director | March 21, 2024 |
| William White MPP, J.D. | ||
| /s/ Mona Ashiya | Director | March 21, 2024 |
| Mona Ashiya, Ph.D. | ||
| /s/ Mark Chin | Director | March 21, 2024 |
| Mark Chin, MS, MBA | ||
| /s/ Georges Gemayel | Director | March 21, 2024 |
| Georges Gemayel, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.